LIBIFU® (Dolasetron Mesylate)

CN EN

Stock code: 002653.SZ

Home

News

Innovation

Pipeline R&D Platforms

Products

Product List Product Topics Pharmacovigilance

Investors

Stock Information Company Announcements Market Data Q&A Investor Hotline

Join Us

Talent Philosophy Careers

About Haisco

About Us Business Presence

GLOBAL

English China

LIBIFU® (Dolasetron Mesylate)

Drug Introduction

Libifu® (Dolasetron Mesylate Injection) is indicated for the prevention of nausea and vomiting associated with initial and repeated courses of emetogenic cancer chemotherapy (including high-dose cisplatin), prevention of postoperative nausea and vomiting, and treatment of postoperative nausea and/or vomiting.

References

[1] Dolosomide sulfonic acid injection product manual.

[2]. Chen Yuan, Liu Huaimin, Fang Yong. Medical Herald, 2021, 40(10): 1371-1376

Download prescribing information

Long-lasting and convenient

Once Daily Dosing, Rapid and Long-lasting Effect^[1]

First-line antiemetic

A first-line therapy for comprehensive prevention and treatment of nausea and vomiting^[2-3]

Suitable for children

A 5-HT₃ receptor antagonist that can be safely used in children aged 2 to 16 years^[4]

User-friendly

Dolasetron has a favorable safety profile, and no dose adjustment is required for special populations.^[5]

Academic Research Implementation and Inclusion in Multiple Guidelines

In recent years, 8 relevant academic papers have been published, including in authoritative journals such as Chinese Pharmaceutical Journal and Herald of Medicine, covering research areas including prevention and treatment of chemotherapy-induced nausea and vomiting, management of postoperative nausea and vomiting, and drug combination efficacy. It has been formally included in 7 authoritative guidelines and expert consensus statements, including the CSCO Guidelines for the Prevention and Treatment of Nausea and Vomiting Caused by Antitumor Therapies(2025 Edition), Guidelines for the Diagnosis and Treatment of Postoperative Nausea and Vomiting (2025 Edition), and Guidelines for China Prevention and Treatment of Nausea and Vomiting Caused by Antitumor Therapies (2023 Edition).

Successfully included in the National Basic Medical Insurance Catalog in 2017. As of May 2026, it has been used in 1368 medical institutions, benefiting a cumulative total of 12.38 million patients.

Academic Research Implementation and Inclusion in Multiple Guidelines

Frequently Asked Questions

Common Questions and Answers

Libi Fu® (Dolosomide Sulfonic Acid Injection) Common Questions and Answers

What are the main indications for Libridep® (Dolosomib mesylate) in anti-tumor treatment?

Used to prevent nausea and vomiting caused by initial and repeated cytotoxic chemotherapy (including high-dose cisplatin).

What are the indications for Librifor® (Dolosomide Mesylate) in surgical procedures?

Used to prevent post-operative nausea and vomiting, and treat post-operative nausea and/or vomiting.

What is the clinical dosing frequency of Libridep® (Dolosergue mesylate)?

The drug only needs to be administered once a day, offering the clinical advantage of “fast and lasting” absorption.

What is the clinical status of Libridex® (Dolosomide Sulfonic Acid) among anti-emetic drugs?

It is a key medication used for comprehensive prevention and treatment of nausea and vomiting.

LibiFu® (Dolosomide) belongs to which type of target antagonist?

It is a highly selective 5-hydroxytryptamine 3 (5-HT3) receptor antagonist.

Can Liji Fu® (Dolosomib mesylate) be safely used in pediatric patients?

It has excellent child safety data and can be used safely for children aged 2-16.

Which cancer authority organizations have recommended Liji Fu® (Dolosomide Mesylate)?

It has received consistent recommendations from various authoritative guidelines including CSCO (Chinese Society of Clinical Oncology) and NCCN (National Comprehensive Cancer Network).

Which international organization has recommended LibiFu® (Dolosomide Mesylate) for pediatric use?

Recommended by the WHO (World Health Organization) Children’s Medication List as a first-line anti-nausea drug for children.

As of May 2026, how many related academic papers has Librifor® (Dolosomide Mesylate) been published?

8 core academic papers have been published in print.

In which authoritative journals have the research on Liji Fu® (Dolosomide) been published?

Including core domestic medical journals such as "China Pharmaceutical Journal" and "Medical Herald".

What research areas does the academic study of Lijiufu® (Dolosomide) cover?

It covers various aspects such as the prevention and treatment of nausea and vomiting caused by chemotherapy, the management of postoperative nausea and vomiting, and the effects of combined drug use.

As of May 2026, how many authoritative guidelines have included Librifed® (Dolosomide Mesylate)?

It has been officially included in 7 authoritative guidelines and expert consensus.

Which oncology antiemetic guidelines specifically include Libridex® (Dolasetron Mesylate)?

Including the "CSCO Guidelines for the Prevention and Treatment of Nausea and Vomiting Related to Antitumor Therapy 2025" and the "Chinese Guidelines for the Prevention and Treatment of Nausea and Vomiting Related to Antitumor Therapy (2023 Edition)" etc.

Which surgical post-operative treatment guidelines include Libridex® (Dolosomib mesylate)?

Including authoritative clinical guidelines such as the "Postoperative Nausea and Vomiting Management Guidelines (2025 Edition)".

When did Libi Fu® (Dolosomib mesylate) enter the medical insurance list?

In 2020, the first medical insurance negotiation was carried out, and in 2021, it was successfully included in the national medical insurance list.

As of May 2026, what is the current number of medical institutions covered by Libico® (Dolosergolemsulfonic acid)?

Currently, 1,368 medical institutions across the country have officially adopted and widely utilized these technologies.

As of May 2026, how many people have been benefited by Librifor® (Dolosomide Mesylate)?

The clinical program has benefited over 12.38 million patients.

What is the significant advantage of Libridep® (Dolosomide Sulfonic Acid) in anti-emetic treatment in pediatrics?

It is a rare drug that can be safely used for children aged 2–16 years and is a first-line antiemetic agent for 5-HT3 receptor antagonists recommended by the World Health Organization.

What is the summary of the core advantages of Libridep® (Dolasetron Mesylate) in preventing vomiting during chemotherapy and after surgery?

It has the comprehensive advantages of rapid effectiveness and durability once a day, official inclusion in multiple top domestic and international guidelines, and solid clinical evidence-based support.